Apoptotic-Cell Accumulation and Mertk Expression Are Linked to Diminished Antiviral CD8+ T Cell Immunity in Chronic Infections Authors: Tom Adomati, Thamer A. Hamdan, Hilal Bhat, Murtaza Ali, Namir Shaabani, Lamin B. Cham Published: 2026 ABSTRACT Exhaustion of antiviral immunity driven by inhibitory signals is one hallmark of persistent viral infection. Notably, PD-1 and IL-10 are two major contributors to CD8+ T cell dysfunction. How these molecules are specifically induced during chronic viral infection remains mainly unknown. Using the lymphocytic choriomeningitis virus model, we show that the apoptotic-cell accumulation and expression of tyrosine kinase Mertk are linked to the outcome of chronic viral infection. Early CD8+ T cell activation correlated with increased dead-cell deposition, rapid induction of IL-10 and TGF-β in macrophages and dendritic cells (DCs), and a pronounced upregulation of PD-1 on CD8+ T cells and its ligand PD-L1. In TCR-β-deficient mice lacking CD8+ T cells, dead-cell generation and expression of IL-10, TGF-β, PD-1, and PD-L1 were markedly restricted. Our findings suggest that CD8+ T cell-mediated killing of infected targets generates large quantities of apoptotic cells, which activate the phosphatidylserine-binding kinase Mertk on macrophages and DCs. This signalling cascade subsequently promotes expression of IL-10, TGF-β, PD-1, and partially PD-L1. Consistent with this model, loss of Mertk in Mertk−/− mice reduced inhibitory cytokines and PD-1 expression, accelerated antiviral CD8+ T cell responses, and improved viral control. Collectively, our study provides important insight into cellular basis of T cell regulation identifying apoptotic cells and Mertk activation as key mechanisms initiating the suppression of CD8+ T cell immunity during chronic viral infection. INTRODUCTION Chronic viral infections, such as HIV, hepatitis C virus, and hepatitis B virus remain a major global health burden (1). CD8+ T cells are essential for clearing these intracellular pathogens and are central to the host’s ability to prevent chronic infection (234). CTLs kill their target cells by triggering apoptosis (56). CTLs lyse infected cells through perforin- and Fas-mediated pathways (7). The fate of effector CD8+ T cells differ between acute and chronic viral infections. During acute viral infection, virus-specific effector CD8+ T cells greatly expand, secrete copious amounts of inflammatory cytokines that influence cytolytic activities of virus-infected cells resulting in efficient clearance of infection (8). In chronic viral infection, a large-scale expansion of effector CD8+ T cells occurs but the virus is not cleared and persists for months to years in several organs (910) and can lead to lifelong immunosuppression (11). Persistence exposure to viral Ags in presence of sustained inhibitory signals drives the differentiation of virus-specific CD8+ T cells into functionally exhausted state (10121314). Thus, viral infections not only trigger inflammatory signals but also suppressive cues that can temporarily restrain immune activation (15). How these inhibitory signals are induced at the peak of CD8+ T cells activation during chronic viral infection remains poorly understood. In lymphocytic choriomeningitis virus (LCMV) infection, immunosuppression attributed to CD8+ T cell-mediated immunopathology has been described (16). For example, destruction of LCMV clone 13-infected dendritic cells (DCs) by CD8+ T cells led to generalized immune suppression (17). In chronic LCMV infection, PD-1 and IL-10 are key inhibitory factors that drive T cell suppression and facilitate viral persistence (41819). Moreover, enhanced IL-10 and TGF-β expression by monocyte derived dendritic cells (moDCs) during hemophagocytosis has been shown to suppress CD8+ T cells response in chronic LCMV infection and this dependent on IFN1 induced phosphatidylserine (PS) on the RBCs and the PS receptor on moDCs. Notably, inhibition of hemophagocytosis limited PD-1 expression on CD8+ T cells (20). Identifying signals that drive such immune unresponsiveness during chronic infection remains one major goal to understand mechanism of immune insufficiency. Mertk, Axl, and Tyro3 comprise the TAM receptor family, with Mertk acting as a principal phagocytic receptor that senses PS on apoptotic cells through its bridging ligands. In mice, Mertk is predominantly expressed on the surface of macrophages and DCs, where it mediates macrophage binding to apoptotic cells and facilitate their phagocytosis (2122). Interestingly, apoptotic cells can induce both expression (23) and activation of Mertk (242526) resulting in reduced secretion of pro-inflammatory cytokines in DCs in vitro (27) and this suppressed innate immune response by inhibiting DC activation in animal models (28). Evidently, unlike human counter parts (29), murine T and B cells and several other immune cell populations don’t express Mertk at steady state (3031). In contrast, Mertk is aberrantly expressed across a wide range of liquid and solid malignancies (3233343536373839). Previously, using the highly cytopathic vesicular stomatitis virus (VSV) as acute infection model, we showed that dead cells can induce innate anergy and that Mertk serves as a key regulatory signal (40). In the present study, we extend these findings by demonstrating that CD8+ T cell activation during chronic LCMV infection correlates with increased accumulation of apoptotic cells and increased Mertk expression, ultimately limiting antiviral CD8+ T cell responses and impairing viral control. Conceivably, PS exposure on apoptotic cells becomes ligand-coated and functions as a potent activator of Mertk, leading to the induction of IL-10, TGF-β, and PD-1, thereby suppressing antiviral immunity. The observation that apoptotic-cell induction parallels increased IL-10, TGF-β, and PD-1 expression may help explain why these inhibitory pathways are preferentially upregulated during infection with persistent LCMV strains. Consistent with this model, Mertk deficiency reduced IL-10 and TGF-β production in Ag-presenting cells (APCs) and limited PD-1 expression on CD8+ T cells, resulting in enhanced antiviral CD8+ T cell responses. MATERIALS AND METHODS Ethics statement Animal experiments were authorized by the Veterinary Office of North Rhine-Westphalia (Veterinäramt Nordrhein-Westfalen; Düsseldorf-Essen, Germany) and conducted in accordance with the German laws for animal protection or according to institutional guidelines at the Ontario Cancer Institute of the University of Toronto Health Network. All animal experiments approved under license number 2016.A289.G1569 from the State Agency for Nature, Environmental and Consumer Protection of North Rhine-Westphalia (Landesamt für Natur, Umwelt und Verbraucherschutz Nordrhein-Westfalen). All animal care and use protocols adhered to national animal protection laws (Tierschutzgesetz) and European laws (Directive 2010/63/EU) and regulations, as well as Federation of European Laboratory Animal Science Associations (http://www.felasa.eu/) guidelines. Animals were put to death by cervical dislocation. Mice Mertk–/– mice were bred heterozygously onto a Sv129 × C57BL/6 (B6) background. F5 (F5 generation from backcross with B6) Mertk–/– mice were directly compared with littermate controls (Mertk+/+ mice). All other mice used in this study were maintained on a C57BL/6 background. Virus and focus formation assay LCMV-docile and WE were originally obtained from F. Lehmann-Grube (Heinrich Pette Institute, Hamburg, Germany) and was propagated on L929 cells (obtained from ATCC, NCTC clone 929). LCMV-docile was donated by Prof. Dr. R. Zinkernagel (University of Zurich, Zurich, Switzerland) and was propagated on L929 cells. Mice were infected intravenously (i.v) with either 2×106 plaque-forming units (PFU) of LCMV-docile or WE. LCMV viral titres were detected by a focus-forming assay on MC57 fibroblasts, as previously described. In brief, organs were smashed in DMEM containing 2% fetal calf serum (FCS), titrated 1:3 over 12 steps in 96-well round-bottom plates, and plaqued on MC57 cells. After incubation for 3 h at 37°C, the overlay was added (1:1 mixture of methyl cellulose and Iscove’s modified Dulbecco’s medium), and the virus preparation was again incubated at 37°C. Plaques were counted 48 h later by LCMV nucleoprotein (NP) staining. For staining, cells were fixed with 4% formaldehyde solution in PBS, permeabilized with 1% Triton-X solution in PBS, blocked with 10% FCS in PBS, and stained with rabbit anti-LCMV NP Ab (made in-house). Enhanced chemiluminescence-conjugated anti-rabbit-IgG Ab (from Jackson ImmunoResearch, West Grove, PA, USA) was used as a secondary Ab (diluted 1:400 to the original concentration in distilled water). Plaques were detected by chemiluminescence (0.2 M Na2HPO4 + 0.1 M citric acid + 30% H2O2 + o-phenylenediamine dihydrochloride; all chemicals from Sigma-Aldrich, Saint Louis, MO, USA). Genotyping by PCR The tail lysis buffer containing proteinase K was used to digest the tail samples overnight. DNA was extracted by the phenol/chloroform method (41). The following oligonucleotide primers that detect murine Mertk were used: 1) Mertk+/+ primer, 5′-TTC TTG TTC TGG GGT TGA CTC-3′; 2) common sense primer, 5′-CAT CTG GGT TCC AAA GGC TA-3′, a common sense primer that detects both sequences; and 3) Mertk–/– primer, 5′-ATC AGC AGA CTC TGT TCC AC-3′ (all from biomers.net, Ulm/Donau, Germany). The product was analysed on 2% agarose gels in Tris-borate-EDTA buffer and visualized by ethidium bromide staining. Bone marrow chimeras For generation of bone marrow chimeras, Mertk+/+ mice and Mertk–/– mice were irradiated with a single dose of 9.5 Gy from x-ray source in one fraction. After 24 h, mice were reconstituted i.v with 10×106 bone marrow cells from either Mertk+/+ or Mertk–/– mice. After 30 days of reconstitution, the mice were infected with 2×104 PFU of LCMV-docile. On day 8, the percentage or an actual number GP33+CD8+ T cells and intracellular IFN-γ+ cells and TNF-α+ cells were performed as previously described above; in addition, cells were stained with anti-PD-1 (53–6.7 and anti-CD86 Abs; all from eBioscience, Waltham, MA, USA). All Abs were diluted 1:100 to their original concentration in FACS buffer. All stained cells were analysed on either an LSRII or an FACS LSRFortessa flow cytometer (BD Biosciences), and data were analysed with FlowJo software (Ashland, OR, USA). Method details Histology Histologic analyses of snap-frozen tissue were performed with a monoclonal Ab to LCMV glycoprotein (VL4; made in-house). Anti-active caspase-3 (C92-605), anti-CD8, anti-F4/80, anti-PD-L1, anti-PD-1, and anti-Mertk (DSSMMER) monoclonal Abs were purchased from eBioscience. Sections for caspase-3 staining were washed and stained with streptavidin (eBioscience). In brief, sections were fixed with acetone, and nonspecific Ags were blocked for 15 min in PBS containing 2% FCS or for 1 h in PBS containing 10% FCS (anti-caspase-3). They were then stained for various Abs and diluted 1:100 in blocking solution for 1 h (Vi10 and anti-Mertk) or 2 h (anti-active caspase-3). Images of stained sections were acquired with a fluorescence microscope (BZ-II analyzer; KEYENCE, Osaka, Japan). Flow cytometry For surface staining of PS on dead cells, spleens were dissociated in annexin buffer, and splenocytes were incubated with annexin V (PI; eBioscience) and 7-AAD (BioLegend, Koblenz, Germany) for 30 min at room temperature. For measurement of surface staining, spleens were dissociated in FACS buffer, the samples were stained with anti-CD11b (53–6.7), anti-CD11c (53–6.7), anti-F4/80, anti-MHCII, anti-Mertk (eBioscience), for 30 min at 4°C and for intracellular IL-10 and TGF-β measurement, splenocytes were fixed with formaldehyde (2% formaldehyde solution in PBS) for 10 min, permeabilized with saponin (1%) solution, and stained with anti-IL-10 and TGF-β Ab (eBioscience). Tetramers Tetramers were provided by the Tetramer Facility of the National Institutes of Health (NIH; Bethesda, MD, USA). Cells were stained with allophycocyanin-labelled GP33 (GP33/H-2Db) or (NP396/ H-2Db) tetramers for 15 min at 37°C. After incubation, the samples were stained with anti-CD8 (53–6.7; eBioscience), anti-PD-1, anti-PD-L1 for 30 min at 4°C. For blood samples, erythrocytes were lysed with 1 ml BD lysing solution (BD Biosciences), washed once with FACS buffer, and analyzed by flow cytometry. Absolute number of GP33-specific CD8+ T cells were calculated by FACS analysis using fluorescing beads (BD Biosciences). For measurement of intracellular IFN-γ and TNF-α, cells were fixed with formaldehyde (2% formaldehyde solution in PBS) for 10 min, permeabilized with saponin (1%) solution, and stained with anti-IFN-γ (XMG 1.1) or TNF (MP6-XT22) Abs (eBioscience). Intracellular cytokine staining (ICS) For ICS, splenic tissue was homogenized, and splenocytes were restimulated with LCMV-GP33-specific peptide (PolyPeptide Laboratories, Strasbourg, France) for 6 h. Brefeldin A was added 1 h after stimulation, and samples were incubated at 37°C, then incubated with surface and intracellular markers at 4°C, as described above. Cell surface staining to determine CTL activity was performed with BD reagents as described. In short, T cell Abs, anti-CD8, anti-KLRG1 (1D4B) and anti-CD44 (1B11) (BD Biosciences) were used for surface staining. Intracellular granzyme B and perforin (GB12, Caltag Laboratories, Carlsbad, CA, USA) staining was performed with the Cytofix/Cytoperm Intracellular Staining Kit (BD Biosciences) after a 4 h stimulation of splenocytes with anti-CD3e (500A2) and anti-CD28 (37.51; BD Biosciences) Abs. In vivo depletion of CD8+ lymphocytes We administered intraperitoneally (i.p) 3 doses of anti-CD8a depletion Ab (BE0090) or the isotype control (BE0011) (all from BioXcell USA, Lebanon, NH, USA) at 2.5 mg/mouse in PBS. The extent of CD8+ T cells depletion was determined 1) in peripheral blood by flow cytometric staining and complete blood counts as both the number of cells/mm3 of blood and the percentage of CD3+ T cells and 2) in tissues by flow cytometry and measurement of the level of CD8+ T cells as a fraction of their pre-depletion frequency. Adoptive transfer For splenocyte transfer experiments, 1×104 splenocytes from Mertk+/+ or Mertk–/– mice were injected i.v into RAG1–/– mice. One day later, mice were infected with 2×104 PFU of LCMV-docile. On day 10, the percentage or an actual number GP33+CD8+ T cells were stained as described above; in addition, cells were stained with anti-PD-1 (53–6.7 Abs; all from eBioscience). To check the expression of surface markers, cultured cells were stained with anti-PD-1 (RMP1-30; Invitrogen, RMT3-23; BioLegend), and anti-CD44 (Pgp-1, Ly-24; eBioscience) Abs. All Abs were diluted 1:100 to their original concentration in FACS buffer. For determination of total cell numbers, FACS beads were used (BD Biosciences). Treatment with PS-based liposome (CPS-514) PS-based liposome (catalog No.CPS-514; Encapsula Nanosciences, Brentwood, TN, USA). It was ready to use product already diluted in PBS and then administered i.p at a dose of 50 ng/mouse on day 5, 6, and 7 after infecting the mice with 2×104 PFU of LCMV-docile. RT-PCR Total RNA was extracted from the spleen with TRIzol reagent (Ambion, Foster City, CA, USA) according to the manufacturer’s instructions. RNA was transcribed with a QuantiTect Reverse Transcription Kit (QIAGEN, Hilden, Germany). Quantitative RT-PCR amplification of target gene was performed with SYBR Green quantitative PCR master mix in a Light Cycler 480 (Roche, Indianapolis, IN, USA). QuantiTect Primer assay for suppressors of cytokine signalling (SOCS3, Cat # 52113S; RRID: AB_2799408, Cell Signalling) was used for quantification of mRNA expression. For analysis, expression level of target gene was normalized to GAPDH, 18S ribosomal RNA (QIAGEN) or both as an internal control gene (ΔCt). Gene expression value was then calculated with the ΔΔCt method. Relative quantity (RQs) was determined with the equation RQ¼=2-ΔΔCt. Quantification and statistical analysis Statistical analyses were performed using GraphPad Prism version 10.4.2 (GraphPad Software, Boston, MA, USA). Data are expressed as mean ± SEM. Student’s t-test was used to detect statistically significant differences between groups. Significant differences between several groups were detected by one-way ANOVA with Bonferroni or Dunnett post hoc tests. The level of statistical significance was set as p<0.05, p<0.01, p<0.001, and p<0.0001. RESULTS CD8+ T cell activation during chronic LCMV infection correlates with increased accumulation of apoptotic cells and induction of inhibitory molecules During chronic LCMV infection, the peak of CD8+ T cell activation typically occurs around day 8, coinciding with maximal viral replication (4243). We speculated that apoptotic cells generated by CTL activity might influence the outcome of the adaptive immune response. To explore this, we analysed active caspase-3 in naïve and infected spleens at 24 h, 5 days, and 8 days after infection with 2×106 PFU of the LCMV-docile strain. Unlike naive mice and earlier time points, spleens from day 8 post-infection showed a marked increase in apoptotic cells, as indicated by detectable active caspase-3 (Fig. 1A). Flowcytometry further confirmed elevated frequencies of apoptotic cells at this time point, as shown by annexin V staining (Fig. 1B). Importantly, the absence of CD8+ T cells in TCR-β deficient mice abolished active caspase-3 expression (Fig. 1C and D), indicating that apoptosis results from effector CD8+ T cell activity rather than direct viral cytopathicity. Consistent with this, CD8+ T cell infiltration into the liver on day 8 correlated with increased apoptosis, whereas CD8+ T cell deficiency markedly reduced the presence of dead cells (Fig. 1D). We further propose that IL-10 release during chronic infection depends on CD8+ T cell-mediated cytolysis of infected targets. Supporting this, TCR-β knockout mice exhibited reduced frequencies of IL-10+ and TGF-β+ cells (Fig. 1E). Histological analysis also revealed diminished PD-L1 and PD-1 expression in TCR-β-deficient mice (Fig. 1F), consistent with the absence of CD8+ T cell driven immunoregulatory signals. Taken together, these findings indicate that the induction of apoptotic cells during chronic LCMV infection is closely linked to CD8+ T cell activity and is accompanied by increased expression of key immunoregulatory molecules that shape T cell responses and function. CD8+ T cell activation during chronic LCMV infection correlates with increased accumulation of apoptotic cells and induction of inhibitory molecules. (A) Spleen sections for active caspase-3 (green) of C57BL/6 (WT) mice infected i.v with 2×104 PFU LCMV-docile (naïve; 24 h; day 5; day 8; n=4). (B) FACS of splenocytes for 7AAD and annexin V of these mice (naïve; 24 h; day 5; day 8; n=4). (C) Spleen sections for active caspase-3 (green) and CD8 (red) of WT or TCR-β–/– mice infected i.v with 2×104 PFU LCMV-docile (naïve; day 8; n=5). (D) Liver sections for Active Caspase-3 (green) and CD8 (red) of these mice (naïve; day 8; n=5). (E) FACS of splenocytes for IL-10 and TGF-β of these mice (naïve; day 8; n=5).(F) Spleen sections for PD-1 (green) and PD-L1 (red) of these mice (naïve; day 8; n=5). The data are shown as mean ± SEM. Data were analyzed using a parametric Student’s t-test. *p<0.05; ***p<0.001; ****p<0.0001. CD8+ T cells activation is accompanied by the induction of Mertk signalling and downstream inhibitory mechanisms Since Mertk functions as a sensor of externalized PS on apoptotic cells, we hypothesized that CD8+ T cell–mediated cytolysis may generate apoptotic targets that engage Mertk and thereby trigger additional immunoregulatory pathways that limit CD8+ T cell responses during chronic infection. In contrast to DCs and macrophages, prior studies and our own earlier findings have shown that murine CD8+ T cells do not express Mertk under steady-state conditions (31). Histologically, we first observed increased Mertk expression in the spleens of wild-type (WT) mice infected with the chronic LCMV-docile strain compared with naïve controls (Fig. 2A). This induction was partially dependent on CD8+ T cell activation, as TCRβ-deficient mice lacking CD8+ T cells exhibited reduced Mertk expression (Fig. 2B). We further confirmed that CD8+ T cells lacked Mertk expression in both naïve and activated states (Supplementary Fig. 1A and B), indicating that Mertk-mediated regulation of T cell responses occurs indirectly through APCs. Our earlier work using a VSV infection model demonstrated that Mertk regulates the expression of SOCS1 and SOCS3, with VSV cytopathicity serving as the primary trigger. In the present LCMV model, SOCS1 and SOCS3 induction was partially dependent on CTL activity (Fig. 2C), and expression of both suppressors was diminished in Mertk–/– mice (Supplementary Fig. 1C). To explore how Mertk drives immunosuppression, we assessed IL-10 production. Mertk deficiency reduced the frequency of IL-10+ cells (Fig. 2D). Notably, IL-10 levels were higher during chronic infection compared with acute LCMV WE infection (Fig. 2E). Moreover, exogenous IL-10 treatment increased SOCS3 expression in WT mice (Supplementary Fig. 1D), supporting the existence of a Mertk–IL-10–SOCS regulatory axis. Given these findings, we speculated that Mertk-dependent, T cell–extrinsic immunoregulatory pathways such as IL-10 and SOCS induction in APCs may promote cell-intrinsic inhibitory mechanisms in CD8+ T cells, including PD-1 expression. Indeed, Mertk+/+ mice exhibited significantly higher PD-1 expression on total and virus-specific CD8+ T cells, whereas this upregulation was markedly reduced in Mertk–/– mice (Fig. 2F and G). In contrast, PD-L1 expression remained unchanged (Fig. 2F), suggesting selective regulation of the T cell inhibitory receptor rather than its ligand. Together, these findings identify Mertk as a key upstream regulator of CD8+ T cell responses during chronic viral infection, acting through APC-mediated induction of immunosuppressive cytokines and inhibitory signalling pathways. CD8+ T cells activation is accompanied by the induction of Mertk signalling and downstream inhibitory mechanisms. (A) Spleen sections for Mertk (red) of WT mice infected i.v with 2×104 PFU LCMV-docile (naïve; day 8; n=5). (B) FACS of splenocytes for Mertk of WT or TCR-β–/– mice infected i.v with 2×104 PFU LCMV-docile (naïve; day 8; n=5). (C) Spleen sections for SOCS1 and SOCS3 (green) of these mice (naïve; day 8; n=5). (D) FACS of splenocytes for IL-10 of Mertk+/+ or Mertk–/– mice infected i.v with 2×104 PFU LCMV-docile (naïve; day 8; n=5). (E) FACS of splenocytes for IL-10 of Mertk+/+ or Mertk–/– mice infected i.v with 2×104 PFU LCMV-docile or 2×104 PFU LCMV WE (naïve; day 8; n=5). (F) Spleen sections for PD-1 (green) and PD-L1 (red) of Mertk+/+ or Mertk–/– mice infected i.v with 2×104 PFU LCMV-docile (naïve; day 8; n=5). (G) Percentage and absolute number of PD1+CD8+ T cells in blood of these mice (naïve; day 8; n=3). The data are shown as mean ± SEM. Data were analyzed using a parametric Student’s t-test. ***p<0.001; ****p<0.0001. Apoptotic cell generation by CD8+ T cells is linked to the activation of Mertk signalling and the subsequent induction of inhibitory cytokine production Loss of perforin in Perforin–/– mice resulted in reduced active caspase-3 expression (Fig. 3A), indicating diminished cytolytic activity, which corresponded with a marked decrease in IL-10+ and TGF-β+ cells (Fig. 3B). Consistently, both total CD4+ and CD8+ T cells from Perforin–/– mice exhibited reduced production of IL-10 and TGF-β (Fig. 3C, Supplementary Fig. 2A). To assess the contribution of CD8+ T cells to this regulatory environment, we depleted CD8+ T cells in Mertk+/+ and Mertk–/– mice or treated them with isotype control Abs as outlined in Supplementary Fig. 2B and C, followed by infection with an equivalent dose of LCMV-docile strain. CD8+ T cell depletion led to a general reduction in IL-10 production by DCs and macrophages, with the most pronounced decrease observed in Mertk–/– mice (Fig. 3D). Despite this reduction, we observed a compensatory increase in TGF-β production by DCs and macrophages, as well as elevated IL-10 and TGF-β expression in total CD4+ T cells following CD8+ T cell depletion, all in a Mertk-dependent manner (Fig. 3E). To directly evaluate Mertk activation in vivo, mice were treated with PS-based liposomes or PBS during LCMV infection (Supplementary Fig. 2D). PS-liposome-treated WT mice displayed increased frequencies of IL-10+ and TGF-β+ cells compared with Mertk–/– mice (Fig. 3F, Supplementary Fig. 2E). Together, these findings demonstrate that apoptotic cell generation and Mertk signalling are tightly linked to the induction of inhibitory cytokines during viral infection. Apoptotic cell generation by CD8+ T cells is linked to the activation of Mertk signalling and the subsequent induction of inhibitory cytokine production. (A) Spleen sections for active caspase-3 (green) of WT or Perforin–/– mice infected i.v with 2×104 PFU LCMV-docile (naïve; day 8; n=3). (B) FACS of splenocytes for IL-10 and TGF-β on DCs and macrophages of these mice (naïve; day 8; n=5). (C) FACS of splenocytes for IL-10 and TGF-β on total CD4+ and CD8+ T cells of WT or Perforin–/– mice infected i.v with 2×104 PFU LCMV-docile (day 8; n=5). (D) FACS of splenocytes for IL-10 and TGF-β on DCs and macrophages of Mertk+/+ or Mertk–/– mice treated with anti-CD8 depletion Ab (2.5 mg/mouse) or isotype control (2.5 mg/mouse) and infected i.v with 2×104 PFU LCMV-docile (day 8; n=5). (E) FACS of splenocytes for IL-10 and TGF-β on total CD4+ and CD8+ T cells of these mice (day 8; n=5). (F) FACS of splenocytes for IL-10 and TGF-β on DCs and macrophages of Mertk+/+ or Mertk–/– mice treated with PS-based liposome (50 ng/mouse) or PBS and infected i.v with 2×104 PFU LCMV-docile (day 8; n=5). The data are shown as mean ± SEM. Data were analyzed using a parametric Student’s t-test. *p<0.05; **p<0.01; ***p<0.001; ****p<0.0001. Mertk and IL-10 deficiency leads to heightened antiviral CD8+ T cells response during chronic infection Because T cells do not express Mertk, we hypothesized that apoptotic target cells eliminated by effector CD8+ T cells engage Mertk on APCs, thereby initiating a negative feedback loop that restrains CD8+ T cell responses during chronic LCMV infection. Consistent with this model, Mertk–/– mice displayed significantly elevated frequencies of both total and virus-specific CD8+ T cells (Fig. 4A, Supplementary Fig. 3A). These mice also exhibited increased proportions of IFN-γ and TNF-α producing CD8+ T cells in the spleen and liver (Fig. 4B and C, Supplementary Fig. 3A). Following peptide restimulation, a greater fraction of virus-specific CD8+ T cells produced IFN-γ in the absence of Mertk (Fig. 4D, Supplementary Fig. 3A). Circulating virus-specific CD8+ T cells were similarly increased in both frequency and absolute number in Mertk–/– mice (Fig. 4E and F), and effector-associated KLRG1+ and CD44+CD8+ T cell subsets were expanded in Mertk–/– mice during chronic infection (Fig. 4G). To determine whether IL-10 contributes to this regulatory pathway, we infected WT and IL-10–/– mice with equivalent doses of LCMV-docile. IL-10 deficiency resulted in increased numbers of virus-specific CD8+ T cells (Supplementary Fig. 3B) and enhanced IFN-γ production (Supplementary Fig. 3C), paralleling the phenotype observed in Mertk–/– mice. Additionally, DCs exhibited increased proliferation in the absence of IL-10 (Supplementary Fig. 3D). Together, these findings suggest that Mertk signalling provides a critical regulatory checkpoint that limits antiviral CD8+ T cell responses during chronic infection, with IL-10 acting as a key downstream mediator of this suppressive pathway. Mertk and IL-10 deficiency leads to heightened antiviral CD8+ T cells response during chronic infection. (A) Percentages and absolute number of Tet-GP33+CD8+ T cells in blood, spleen and liver of Mertk+/+ or Mertk–/– mice infected i.v with 2×104 PFU LCMV-docile (day 8; n=3). (B) Percentages and absolute number of IFN-γ in the spleens and livers of these mice stimulated with GP33 (none; day 8; n=3). (C) Percentages and absolute number of TNF-α in the spleens and livers of these mice (none; day 8; n=5). (D) Percentages and absolute number of IFNγ+Tet-GP33+CD8+ T cells in the spleens and livers of these mice (none; day 8; n=5). (E) Tet-GP33+CD8+ T cells in blood of these mice at indicated time points (day 8; n=5). (F) Absolute number of CD8+ T cells in blood of these mice (day 8; n=5). (G) Percentages of KLRG1+ and CD44+CD8+ T cells in blood, spleen and liver of these mice (day 8; n=3). The data are shown as mean ± SEM. Data were analyzed using a parametric Student’s t-test. *p<0.05; **p<0.01; ***p<0.001; ****p<0.0001. Mertk extrinsically regulates CD8+ T cell responses during chronic infection Considering murine T cells, unlike DCs and macrophages, do not express Mertk, we hypothesized that the effects of Mertk on CD8+ T cell responses are extrinsically mediated. To exclude a T cell-intrinsic role, we adoptively transferred naive splenic T cells from either Mertk+/+ mice or Mertk–/– mice into RAG1–/– recipients, which lack endogenous B and T cells. Twenty-four h later, mice were infected with an equivalent dose of the LCMV-docile strain. Ten days post-infection, Mertk+/+ → RAG1–/– and Mertk–/– → RAG1–/– recipient mice displayed comparable frequencies and absolute numbers of virus-specific CD8+ T cells (Fig. 5A), indicating that Mertk does not regulate CD8+ T cell responses intrinsically. Consistently, PD-1 expression was also similar between the two groups (Fig. 5B). To further assess the contribution of Mertk in APCs, we generated bone marrow chimeras by irradiating Mertk+/+ mice and reconstituting them with bone marrow from either Mertk+/+ or Mertk–/– donors. After 45 days of reconstitution, chimeric mice were infected with LCMV-docile and CD8+ T cell responses were analysed in the spleen and liver. Macrophages and DCs from Mertk–/– →Mertk+/+ chimeras exhibited increased CD86 expression (Fig. 5C), suggesting enhanced costimulatory capacity in the absence of Mertk. Mirroring the phenotype of global Mertk deficiency, Mertk–/– →Mertk+/+ chimeras displayed elevated numbers of virus-specific and total CD8+ T cells (Fig. 5D), along with heightened TNF-α and IFN-γ production (Fig. 5E). These responses were attenuated in Mertk+/+ →Mertk+/+ chimeras, consistent with the phenotype observed in WT mice (Fig. 5D and E). Together, these findings demonstrate that Mertk deficiency enhances CD8+ T cell priming and effector function through APC-mediated mechanisms, identifying Mertk as a key extrinsic brake on antiviral T cell immunity. Mertk extrinsically regulates CD8+ T cell responses during chronic infection. (A) Percentages and absolute number of GP33+CD8+ T cells in spleens of Mertk+/+ → RAG1–/– recipient mice or Mertk–/– → RAG1–/– recipient mice infected i.v with 2×104 PFU LCMV-docile (day 10; n=3). (B) Percentage of PD1+ CD8+ T cells in blood of these mice (day 10; n=3). (C) MFI of CD86 in the spleen of Mertk+/+ → Mertk+/+ chimera mice or Mertk–/– → Mertk+/+ chimera mice infected with 2×104 PFU LCMV-docile (day 8; n=4). (D) Percentages and absolute number of Tet-GP33+CD8+ T cells in blood, spleens and livers of these mice (day 8; n=4). (E) Percentages and absolute number of IFN-γ and TNF-α in the spleens and livers of these mice stimulated with GP33 (none; day 8; n=5). The data are shown as mean ± SEM. Data were analyzed using a parametric Student’s t-test. *p<0.05; **p<0.01; ***p<0.001. Loss of Mertk improves viral clearance but is accompanied by immunopathological consequences Effector analysis revealed that Mertk–/– mice exhibited higher perforin expression compared to Mertk+/+ mice (Fig. 6A), whereas granzyme B levels remained unchanged (Fig. 6A). Consistent with this heightened cytotoxic profile, Mertk–/– mice showed improved control of viral replication (Fig. 6B). Depletion of CD8+ T cells abolished this enhanced viral control across multiple organs (Supplementary Fig. 4A). At earlier time points, viral loads were comparable between the two groups, underscoring the essential role of Ag-specific CTLs in LCMV clearance (Supplementary Fig. 4B and C). To assess the immunopathological consequences of this heightened CD8+ T cell activity, we measured liver transaminases and found that Mertk–/– mice displayed transient elevations (Fig. 6C). Collectively, these findings indicate that Mertk deficiency enhances immune priming by APCs, resulting in more robust effector CD8+ T cell responses that limit viral replication, albeit at the cost of increased immunopathology. Loss of Mertk improves viral clearance but is accompanied by immunopathological consequences. (A) Percentage and absolute number of perforin+CD8+ T cells and granzyme B+CD8+ T cells in the spleens and livers of Mertk+/+ or Mertk–/– mice infected with 2×104 PFU LCMV-docile and stimulated with GP33 (none; day 8; n=5). (B) Viral titres in indicated organs of these mice (day 8; n=5). (C) Serum ALT, AST, and LDH activity of these mice (day 8; n=3). The data are shown as mean ± SEM. Data were analyzed using a parametric Student’s t-test. *p<0.05; **p<0.01; ***p<0.001; ****p<0.0001. DISCUSSION Immunosuppression driven by apoptotic pathways has been widely studied (44). A range of immunosuppressive mediators most notably IL-10, TGF-β, and PGE2 have been widely implicated in shaping immunoregulatory responses (45). Here, we identify a previously underappreciated link between CTL-induced apoptotic cells, Mertk signalling, and the establishment of an immunosuppressive environment during chronic viral infection. We propose that CD8+ T cell cytotoxicity generates apoptotic cells that act as a negative-feedback signal to restrain antiviral immunity through Mertk activation on APCs. In TCRβ-deficient mice, the markedly reduced apoptotic burden is accompanied by diminished IL-10 and TGF-β production in APCs, indicating that CD8+ T cell–driven apoptosis is a key upstream instigator of this immunoregulatory pathway. From mechanistic standpoint, TAM receptors such as Mertk are activated by the vitamin K-dependent ligands Gas6 and Protein S, which bridge externalized PS on apoptotic cells and microvesicles to Mertk-expressing APCs (46). Our data suggest that CTL-generated apoptotic cells are a major trigger for Mertk activation, as TCR-β deficient mice showed minimal Mertk expression. SOCS is a known negative regulator for various cytokine signalling (4748). Downstream, Mertk signalling induces SOCS1 and SOCS3, key inhibitors of cytokine and TLR pathways (4950). Consistent with our previous findings using a highly cytopathic VSV infection model, SOCS1 and SOCS3 expression remained Mertk-dependent in the LCMV model, although here CTLs serve as the primary instigator. The observation that IL-10 treatment increases SOCS3 expression in WT mice supports a streamlined Mertk–IL-10–SOCS axis in which Mertk-dependent cues promote IL-10 production, and IL-10 in turn induces SOCS to restrain pro-inflammatory cytokine signalling. This framework suggests that SOCS acts as a critical effector reinforcing Mertk-driven immune resolution, and that disruption of this axis shifts DCs and macrophages toward heightened inflammatory responsiveness. Our findings position Mertk as a key upstream regulator of anti-inflammatory signalling. Chronic viral infections such as HIV have been shown to promote the emergence of immunoregulatory CD8+ T cells that produce IL-10 and suppress CD8+ T cell responses in a non–Ag-specific manner (51). Moreover, HIV-specific CD8+ T cells can themselves produce IL-10 and TGF-β, further contributing to impaired antiviral immunity (525354). Consistent with these observations, we also found increased frequencies of IL-10 and TGF-β–producing T cells in WT mice in our chronic infection model, and genetic ablation of perforin in Perforin–/– mice correlated with reduced suppressive cytokine production. This suggests that effector function drives the initiation of immune-regulatory processes as a consequence of performing cytotoxic activity. However, it remains unclear whether these inhibitory cytokine producing T cells represent LCMV-specific effector cells or a broader regulatory T cell subset. Defining their Ag specificity and lineage identity including potential overlap with emerging regulatory CD8+ T cell populations will be essential for clarifying their functional role in chronic infection. Notably, compared with acute infection, we observed higher frequencies of IL-10+ and TGF-β+ cells during chronic LCMV infection and both populations were regulated by Mertk. Several features unique to chronic infection could account for this shift; Persistent high viral loads and sustained CTL activity generate a continuous apoptotic burden, in contrast to the brief apoptotic wave characteristic of acute infection. This ongoing cell death increases PS availability, promoting more frequent Mertk engagement on APCs; Chronic infection also involves recurrent tissue injury, stromal turnover, and bystander cell death, further expanding the pool of PS-bearing substrates. In parallel, prolonged Ag exposure and inflammatory exhaustion can reprogram DCs and macrophages toward more tolerogenic states, potentially enhancing Mertk expression or sensitivity to PS-mediated cues. Although we did not directly quantify Mertk expression, apoptotic burden, PS-exposure, or SOCS induction in parallel across infection states, these mechanisms are well supported by prior studies and align with our observations. Together, these insights highlight promising avenues for future investigation into how chronic infection reshapes phagocytic and regulatory circuits. We next examined whether Mertk influences the PD-1/PD-L1 axis, a central pathway in T cell exhaustion. In line with the elevated IL-10 and TGF-β production observed in Mertk+/+ mice, we also detected increased PD-1 expression on CD8+ T cells. In contrast, PD-L1 levels remained comparable between genotypes. This divergence suggests that the PD-1/PD-L1 axis may be regulated by distinct cytokine environments, signalling networks, or epigenetic programs downstream of Mertk or other receptors, rather than being uniformly modulated by Mertk activity. These complexities warrant further investigation, particularly given the therapeutic relevance of PD-1/PD-L1 blockade and the potential for targeting Mertk signalling or combining Mertk inhibition with existing immunotherapies. Such approaches may offer clinical benefit but are also likely to introduce immune perturbations. Continued mechanistic studies and carefully designed clinical investigations will be essential to determine how best to harness these strategies. Functionally, Mertk deficiency enhanced CD8+ T cell effector response, reflected by increased perforin expression. Conversely, Perforin–/– mice exhibited reduced active caspase-3 and diminished IL-10 and TGF-β production, underscoring perforin’s dual role in both target-cell killing and shaping immunoregulatory cytokine responses. CD8+ T cell depletion reduced IL-10 production, reinforcing the concept that CTLs act as a double-edged sword essential for viral clearance yet capable of driving immunosuppression through apoptotic-cell generation. Contrary to IL-10, CD8+ T cell depletion unexpectedly increased TGF-β expression in APCs while elevating both IL-10 and TGF-β production by CD4+ T cells, suggesting the activation of a compensatory immunoregulatory reflex. PS-based liposomes mimic naturally exposed PS on apoptotic cells as an “eat-me” signal (55). Consistent with this, treatment of WT mice with PS liposomes induced IL-10 and TGF-β production, further supporting a role for apoptotic cell–derived PS in activating Mertk-dependent immunosuppression. Because Mertk activation in APCs promotes IL-10 production, the reduced IL-10 levels observed in Mertk–/– mice likely contribute to their heightened T-cell priming. IL-10 knockdown in WT mice recapitulated the enhanced T cell priming, response, and functional phenotype, reinforcing the conclusion that IL-10 acts downstream of Mertk signalling to restrain T cell activation. Although Mertk+/+ mice displayed a higher frequency of T cells producing inhibitory cytokines, the molecular pathways governing this regulation and the potential contribution of FOXP3+ regulatory T cells remain unresolved and warrant further investigation. Importantly, we detected no Mertk expression on naive or activated murine T cells, confirming that Mertk acts extrinsically to T cells. Likewise, bone-marrow chimera and adoptive-transfer experiments reinforced this conclusion: Mertk expression on hematopoietic APCs, not T cells, governs the immunoregulatory outcome. The increased CD86 expression in Mertk–/– →Mertk+/+ chimeric mice imply a generally more efficient ability of APCs to prime and engage T cells, consistent with the improved viral control observed in Mertk–/– mice. Finally, CD8+ T cell depletion abolished the enhanced viral clearance in Mertk–/– mice, demonstrating that CTLs are both the drivers and beneficiaries of Mertk-dependent regulation. Our findings reveal a feedback mechanism in which CD8+ T cell cytotoxicity generates apoptotic cells that activate Mertk signalling on APCs, leading to increased IL-10, TGF-β, and PD-1 expression and ultimately dampening antiviral CD8+ T cell immunity during chronic infection. These results identify Mertk as a critical regulator of T cell suppression and a promoter of viral persistence, positioning Mertk-dependent apoptotic-cell sensing as a central mechanism by which chronic infection maintains an immunosuppressive environment. Targeting Mertk may offer a promising antiviral strategy, but the consequences of disrupting this regulatory pathway could also carry significant risks. In particular, the potential for excessive or dysregulated DC, monocyte, and T cell responses underscores the need for careful evaluation in future mechanistic and translational studies.